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Abstract
Numerous copies of endogenous retroviruses are present in the genome of mammals including man. Although most of
them are defective, some, e.g., the human endogenous retroviruses HERV-K, were found to be expressed under certain
physiological conditions. For instance, HERV-K is expressed in germ cell tumours and melanomas as well as in the placenta.
Most exogenous retroviruses including the human immunodeficiency virus HIV-1 induce severe immunodeficiencies and
there is increasing evidence that the transmembrane envelope (TM) proteins of these retroviruses may be involved. We
show here that HERV-K particles released from a human teratocarcinoma cell line, a recombinant TM protein and a peptide
corresponding to a highly conserved so-called immunosuppressive domain in the TM protein of HERV-K inhibit the
proliferation of human immune cells, induce modulation of the expression of numerous cytokines, and modulate the
expression of cellular genes as detected by a microarray analysis. The changes in cytokine release and gene expression
induced by the TM protein of HERV-K are similar to those found previously induced by the TM protein of HIV-1. These data
suggest that the mechanism of immunosuppression may be similar for different retroviruses and that the expression of the
TM protein in tumours and in the placenta may suppress immune responses and thus prevent rejection of the tumour and
the embryo.
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Introduction
In the last years the expression of human endogenous
retroviruses (HERV) in tumours and physiologically healthy
tissues was intensively studied [1–3]. HERV-K is one of the few
human endogenous retroviruses with intact open reading frames
for all viral proteins [4,5]. Non-infectious virus-like particles and
viral proteins have been found in human germ line tumours [6–8]
and melanomas [9–11]. In addition, we have recently shown that
HERV-K proteins are expressed in the human placenta [12].
Antibodies against HERV-K and its TM protein were found in
some tumour patients and pregnant women [1,10,11]. Genes of
other human endogenous retroviruses such as syncytin 1 (the
envelope protein of HERV-W) [13–15] and syncytin 2 (the
envelope protein of HERV-FRD) [16,17] were also found to be
expressed in the placenta. Syncytins play a key role in generating
the syncytiotrophoblast cell layer during placentogenesis by
inducing cell-cell fusion. In animals, the same function is fulfilled
by syncytin-A and syncytin-B in the placenta of mice [18,19], by
syncytin-Ory1 in rabbits [20], syncytin-like env-Cav1 in guinea
pigs [21], syncytin-Car1 in cats and dogs [22], and by enJSRV in
sheeps [23]. It is important to note that these endogenous
retroviruses are not related and that each mammalian species
utilises (‘‘enslaved’’) a different endogenous retrovirus.
Retrovirus infections are frequently associated with tumours
and/or immunodeficiencies. There is increasing evidence that the
transmembrane envelope (TM) proteins of retroviruses including
HIV-1 may contribute to the retroviral immunosuppression [3,24–
26]. Expression of retroviral TM proteins on tumour cells
(originally only growing to tumours in immunocompromised
animals), allowed these cells to grow in immunocompetent
animals, indicating their immunosuppressive property in vivo
[24]. Recently we showed that single mutations in the so called
immunosuppressive (isu) domain of the TM protein gp41 of HIV-
1 per se or in the context of replication competent virus particles
abrogated the modulation of the cytokine release and gene
expression in human peripheral blood mononuclear cells (PBMCs)
induced by gp41 [27]. Furthermore, when studying over 2000
HIV-1 sequences from infected individuals, no sequences with
abrogating mutations were found, indicating that mutated, non-
immunosuppressive HIV-1 may be eliminated by the immune
system [27]. In addition, a peptide corresponding to the isu
domain of gp41 inhibited human PBMCs and modulated the
expression of certain cytokines and other genes as shown in a
comparative transcriptome analysis [28].
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Here we demonstrate that the recombinant TM protein of
HERV-K produced in yeast cells and a synthetic peptide
corresponding to a conserved domain of the TM protein inhibit
the proliferation of human and mouse immune cells, modulate the
release of different cytokines such as the immunosuppressive IL-10
and changes the expression of numerous genes in human PBMCs.
In addition, HERV-K particles produced by human teratocarci-
noma cells also induced IL-10 release. Since the TM protein of
HERV-K was found to be expressed in germ line tumours and
melanomas as well as in the placenta, its expression may
contribute to the growth of the tumour and the protection of the
embryo.
Results
The TM Protein of HERV-K Contains an
Immunosuppressive (isu) Domain
The structure of the TM protein of HERV-K is similar to that
of other retroviruses (Figure 1a). The so-called immunosuppressive
(isu) domain, which is conserved among retroviruses (Figure 1b), is
located in proximity to the N-terminal end of the Cys-Cys loop.
Retroviruses cluster in different groups according to the sequence
of the isu domain. One group includes the gammaretroviruses,
another the lentiviruses with the human (HIV-1, HIV-2) and
simian (SIV) immunodeficiency viruses. HERV-K is different
compared with these groups and contains amino acids from both
groups as well as from another betaretrovirus, the mouse
mammary tumour virus MMTV (Figure 1b). More than 80% of
the published HERV-K sequences contain the isu domain
LANQINDLRQTVIW. In rare cases the sequences LAS-
QINDLRQTVIW and LANQINDLRQSVTW were found
(Table S1), indicating a high conservation of this domain in all
HERV-K proviruses in the human genome.
Characterisation of the TM Protein of HERV-K Produced
in Yeast
To avoid contaminations with bacterial endotoxin, which may
modulate the cytokine release when added to human PBMCs, the
ectodomain of the TM protein of HERV-K was expressed in H.
polymorpha and purified by affinity chromatography. Three
molecules were expressed in transformed cells: 32 kDa, 30 kDa,
and 20 kDa (Figure S1a). All three reacted with an antiserum
induced by immunisation with the recombinant TM protein of
HERV-K produced in E. coli and a serum against the His tag
(Figure S1b, c). Since the predicted molecular weight of the
protein backbone is nearly 17 kDa, we conclude that the proteins
are glycosylated to a different extend. Noteworthy, most probably
due to the glycan chains, the TM protein produced in yeast
reacted less with the antiserum than the TM protein produced in
E. coli that was used for immunisation (Figure S1). As a matter of
fact, at least five epitopes were recognised in the TM protein [11],
and one epitope contained one of the four predicted glycosylation
sites (Figure S1d).
The TM Protein of HERV-K and the Corresponding isu
Peptide Inhibit Activation of PBMCs
To study the influence of the TM protein of HERV-K on the
activation of human immune cells, the purified glycosylated TM
protein produced in yeast cells was added together with the T cell
mitogen Concanavalin A (ConA) to PBMCs from healthy human
blood donors. A significant inhibition of cell activation was
observed when the TM protein of HERV-K was added in
comparison to the bovine serum albumin (BSA) and to the
medium control as measured by two different methods (Figure 2a,
b). This inhibition was dose-dependent. An inhibition was also
observed when another T cell mitogen, phytohemagglutinin
(PHA), was used (data not shown). Noteworthy, the proliferation
assay based on 3H-thymidine incorporation was measuring the
inhibition more efficiently as compared to the Alamar blue assay.
Inhibition of proliferation by the HERV-K TM was also observed
Figure 1. Localisation and sequence of the immunosuppressive
(isu) domain of the TM protein of HERV-K (accession number
Q69384). a, Functional domains of the TM protein: FP, fusion peptide;
FPPR, fusion peptide proximal region; NHR, N-terminal helical region;
ISU, isu domain; C-C, cystein-cystein loop; CHR, C-terminal helical
region; MPER, membrane proximal external region; MSD, membrane
spanning domain. In the amino acid sequence of the isu domain stars
(*) indicate NH2 groups, points (.) mark COOH groups relevant for
polymerisation. b, Sequence comparison of the core (1 corresponds to
the amino acid 552, 14 to 535, acc. Nr. Q69384) of the immunosup-
pressive domain of different retroviruses (MuLV, murine leukaemia
virus; CKS-17 consensus, consensus sequence of the gammaretroviruses
PERV, porcine endogenous retrovirus; HERV-K, -W, -FRD; human
endogenous retroviruses-K, -W, -FRD; HIV-1, -2, human immunodefi-
ciency viruses - 1, -2̧ MMTV, mouse mammary tumour virus; HERV-K,
human endogenous retrovirus-K). Amino acids identical to that in the
first sequence of each group are indicated gray. In addition, amino acids
present in all retroviruses are marked green, in all gammaretroviruses
and HERV-K pink, in HIV-1 and HERV-K orange and in MMTV and HERV-K
blue. In the sequence of HIV-1 the amino acids with high importance
are shown in bold, mutation of these amino acids totally abrogated the
activity to induce IL-10 [27].
doi:10.1371/journal.pone.0070399.g001
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in the case of murine splenocytes, indicating an interspecies effect
(Figure 2c). Finally, carrier protein-conjugates of the peptide
corresponding to the isu domain of the HERV-K TM protein
equally lead to a dose-dependent inhibition of cell proliferation
(Figure 3), narrowing down the inhibitory effect of the TM protein
to this domain.
The TM Protein of HERV-K Modulated Cytokine Release
To analyse the influence of the TM protein of HERV-K on IL-
10 release, PBMCs from two healthy human donors were
incubated for 24 hrs with different doses of the purified protein
and the amount of IL-10 was measured in the supernatant by
ELISA (Figure 4a). Release of IL-10 was analysed because in the
case of the TM protein gp41 of HIV-1 and the corresponding isu
peptide a strong increase in IL-10 release was observed [25,27].
Further on we analysed the influence of the TM protein of HERV-
K on the expression of other cytokines. A microarray assay was
performed to study the expression of 62 cytokines (Figure 4b,
Table S2). An overexpression was observed for the following
cytokines: IL-6, IL-8, IL-10, MCP-1, RANTES, MIP-1alpha,
MIP-1beta, uPAR, sTNFRII, GCSF (for the full names and the
cytokines with unchanged expression at 24 hrs see Table S2).
Similar changes in the cytokine expression were observed when
the isu peptide of the TM protein gp41 of HIV-1 was investigated
in different assays [28].
Donor Dependence of the Immunomodulatory Effect by
the TM Protein of HERV-K
When studying the effect of gp41 of HIV-1 and the
corresponding isu peptide, some differences in the response
among donors were observed [28]. To study this for HERV-K,
PBMCs from 6 healthy human donors (5 male, 1 female, 5
Caucasian, 1 African) were incubated with the same batch and the
same amount of a polymer preparation of the isu peptide of
HERV-K. Reproducible differences in the response were observed
(Figure 5). PBMCs from four donors released a high level of IL-10
(above 250 ng/ml), while PBMCs from two donors released less
than 150 ng/ml, indicating a variable reactivity of the donors to
the isu domain of HERV-K. When PBMCs from a high responder
and from a low responder were tested again after 14 days the same
differences in IL-10 release were observed.
The TM Protein of HERV-K Modulated Gene Expression
To study the influence of the TM protein of HERV-K on gene
expression in human PBMCs, a genome wide microarray analysis
(29.500 genes) was performed. The RNA was isolated from the
PBMCs of a healthy blood donor 24 hrs after incubation with the
TM protein of HERV-K. In this comparative transcriptome
analysis RNA from PBMCs incubated in parallel with medium
alone as well as with the isu peptide of the TM protein gp41 of
HIV-1 was also analysed. When 2.5 mg TM protein of HERV-K
and 12.5 mg isu peptide homopolymer of gp41 of HIV-1 were
added to 36105 cells, both induced release of a similar amount of
IL-10 (810 pg/ml).
Figure 2. Influence of the recombinant TM protein of HERV-K
on the proliferation of ConA-stimulated PBMCs from one
healthy human blood donor (a, b) or murine splenocytes (c).
Cell proliferation was measured using the Alamar blue assay (a, c) or by
3H-thymidine incorporation (b) (mean6SD; n= 3). 3H-thymidine was
added on day three and cells were then harvested one the next day and
the counts per minute were determined, dark gray – isu peptide-BSA
conjugates, gray – BSA conjugates, added at day 0. Black (Pos, positive
control) – medium alone.
doi:10.1371/journal.pone.0070399.g002
Figure 3. Influence of isu peptide-BSA conjugates on the
activation of ConA-stimulated PBMCs from one healthy donor.
Cell proliferation was measured by 3H-thymidine incorporation. The 3H-
thymidine was added on day three and cells were then harvested the
next day and the counts per minute were determined, black - BSA
control, gray – isu peptide-BSA conjugates, added at day 0 (mean6SD;
n = 3). It is a representative experiment out of 5.
doi:10.1371/journal.pone.0070399.g003
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More than 300 genes were found up-regulated and more than
300 genes were found down-regulated upon the incubation with
the TM protein of HERV-K and the isu peptide of HIV-1. Ten
genes of each group (up or down) with the highest fold change
after incubation with the TM protein of HERV-K are shown in
Figure 6. Fifty genes including the first ten genes with the highest
change in expression are shown in Tables S3 (up) and S4 (down).
The expression of the genes up- and down-regulated by the isu
peptide of HIV-1 [28] are also shown for comparison in the Tables
S3 (up) and S4 (down). Nearly the same genes were up- or down-
regulated, however with slight differences. For example, in the case
of the isu peptide homopolymer of HIV-1 IL-6 has the first
position in the list of the most up-regulated and MMP-1 (matrix
metalloproteinase 1) the second, whereas in the case of the TM
protein of HERV-K MMP-1 has the first position and IL-6 the
second.
As mentioned above, the highest up-regulation induced by the
TM protein of HERV-K was shown for the gene of MMP-1
(Figure 6, position 1). MMP-1 is a zinc-dependent protease
essential for the breakdown of the extracellular matrix expressed
on monocytes and macrophages [29]. The second highest up-
regulation was that of the IL-6 gene (Figure 6, position 2),
confirming the results on the protein level as shown by the
cytokine array (Figure 4b). Interestingly, the genes with higher
expression are predominantly involved in two processes ‘‘Immu-
nity and defense’’ and ‘‘Signal transduction’’. Another up-
regulated gene was TREM-1 (triggering receptor expressed on
myeloid cells 1) (Figure 6, position 6). TREM-1 has a role as a
regulator of innate and adaptive immunity [30,31].
Among the down-regulated genes were SEPP1 (selenoprotein P
plasma 1, position 1 in Figure 6), FCN1 (ficolin, position 2 in
Figure 6), as well as FCN2 and TREM2 (position 4 and 6 in
Figure 6). These molecules play an important role in innate
immune responses [32–34].
These results indicate that the recombinant TM protein of
HERV-K produced in yeasts modulated the expression of
numerous genes in human PBMCs and that this modulation is
similar to that induced by the isu domain of the TM protein of
HIV-1.
HERV-K Particles Released from Human Teratocarcinoma
Cells Modulated Cytokine Release
Human GH germ cells express the TM protein of HERV-K on
the cell surface and release pleomorphic non-infectious virus
particles [4,7]. The particles were pelleted and purified by sucrose
cushion centrifugation. By Western blot analysis the presence of
the TM protein in the virus preparation was shown (Figure 7).
Incubation of 36105 human PBMCs with virus particles
containing approximately 10 ng TM protein (for calculation see
Materials and Methods) induced the release of 80 pg IL-10/ml
(Figure 7). Thus the activity of the virus particles is much stronger
than that of the recombinant TM protein produced in yeast cells
and that of peptide polymers. In parallel virus particles of the
porcine endogenous retrovirus (PERV) were pelleted and assayed.
Although approximately the same amount of PERV was added as
calculated by similar amounts of their Gag capsid proteins, the
induction of IL-10 was lower when compared with that induced by
HERV-K (Figure 7).
Discussion
Most retroviruses exert an immunosuppressive effect when a
certain virus load was reached in the infected host. Inactivated
Figure 4. Influence of the HERV-K TM protein on the cytokine
release by donor PBMCs. a, Dose-dependent induction of Il-10
release in PBMCs from two donors by the TM protein of HERV-K (0–
medium control) compared to control protein BSA as measured by
ELISAs (mean6SD; n = 3). b, Cytokine array measuring simultaneous
release of cytokines from human donor PBMCs incubated with the TM
protein of HERV-K, or control protein BSA, or medium alone after 24 hrs
incubation. The up-regulated cytokines are circled. A list of all analysed
cytokines and their full names are given in Table S1.
doi:10.1371/journal.pone.0070399.g004
Figure 5. Influence of the homopolymer of the isu peptide of
HERV-K on the IL-10 release by donor PBMCs. a, Comparison of
the isu peptide homopolymer (grey) with a randomised peptide (dark
grey). b, Comparison of the IL-10 release from PBMCs of six donors
treated with one batch and the same amount of the isu peptide
homopolymer, the IL-10 release of their PBMCs incubated with medium
alone was zero.
doi:10.1371/journal.pone.0070399.g005
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retrovirus preparations, their TM proteins and synthetic peptides
corresponding to the isu domain of their TM proteins were found
to inhibit proliferation of PBMCs and to modulate the cytokine
release and gene expression (for review see [25,26]). Previously we
and others had shown that particles of HIV-1 [27,35], of PERV-A,
PERV-B and the murine leukaemia virus (MuLV) [36], of FeLV
[37,38], of the baboon endogenous retrovirus (BaEV), and of a
deltaretrovirus [39,40] as well as of the Koala retrovirus (KoRV)
[41] were able to inhibit lymphocyte activation and modulated IL-
10 release in treated immune cells.
To extend our studies on the immunosuppressive properties of
retroviruses we investigated a human endogenous retrovirus,
HERV-K. The influence of virus particles released from a human
tumour cell line, of the TM protein and the isu peptide on immune
cell proliferation and gene expression was studied using cytokine
arrays and transcriptome comparison.
We showed for the first time that HERV-K induced IL-10
release from human PBMCs. We also showed that the recombi-
nant TM protein of HERV-K produced in yeast cells and
polymers of a peptide corresponding to the immunosuppressive
domain of the TM protein inhibited immune cell activation, and
modulated cytokine release and gene expression in human
PBMCs.
These data are of importance for the understanding of the role
of endogenous retroviruses in carcinogenesis and embryogenesis.
Previously we and others had shown that the TM protein of
HERV-K is expressed in germ cell tumours and melanomas [11]
as well as in the human placenta [12]. The data presented here
suggest that the expression of the TM protein may contribute to
the suppression of the immune system and thus prevent the
rejection of the tumour cells as well as of the embryo, which
immunologically represents a semi-allotransplant. In fact, an
elevated IL-10 expression was seen in tumour patients as well as in
pregnant women [42–48]. In particular, plasma IL-10 was steadily
increasing during gestation (week 12, p,0.05, week 20, p,0.01
and week 35, p,0.0001, respectively) [42]. Using an antiserum
against the TM protein of HERV-K we found expression of this
protein in the placenta in villous cytotrophoblast and extravillous
cytotrophoblast (EVT) cells invading the decidua [12]. The fact
that EVT cells expressing c-erbB2 coding for the human
epidermal growth factor (EGF) receptor 2 (ErbB2) [49] are
regularly found in intimate contact with maternal immune cells
suggests a potential role of HERV-K in the induction of the
immunosuppression. When such invasive EVT cells were isolated
by ErbB2 affinity chromatography they were found to express the
TM protein of HERV-K at a high level [12]. Noteworthily, in the
placenta at least three other endogenous retroviruses are
expressed, HERV-W, HERV-FRD and ERV-3 [50–52]. The
envelope protein of HERV-W, which is not immunosuppressive
in vivo, corresponds to syncytin-1 and the envelope protein of
HERV-FRD, which is immunosuppressive in vivo, corresponds to
syncytin-2 [50]. The envelope protein of HERV-R (ERV3) is also
Figure 6. Genes with the highest up-regulation (upper part) or
down-regulation (lower part) of their expression in PBMC of
one donor in response to the incubation with the TM protein of
HERV-K. Fold changes indicate gene expression compared to control
cells incubated in medium. The full names of the genes and 40 other
up- or down-regulated genes are given in Tables S2 and S3.
doi:10.1371/journal.pone.0070399.g006
Figure 7. Induction of IL-10 release in human PBMCs by HERV-
K and PERV particles. a, Characterisation and estimation of the
amount of added HERV-K and PERV by SDS-PAGE and Coomassie blue
staining. HERV-K containing 60 ng Gag (capsid, CA) and PERV
containing 100 ng Gag (capsid, CA) were loaded per lane and the
amount of the Gag (CA) proteins was used for comparison. b, Detection
of the TM protein gp36 of HERV-K in the pellet used for incubation with
human PBMCs by a TM specific antiserum, M – marker, control –
pelleted supernatant from uninfected 293 cells, HERV-K – pelleted
supernatant from GH cells. c, IL-10 release by human PBMCs induced by
HERV-K particles, by the pellet from the supernatant of uninfected 293
cells corresponding to the same amount of supernatant (control), and
by purified PERV particles produced on 293 cells. Virus containing
approximately 100 ng Gag (CA) protein, which was used for comparison
(see below) and 10 ng TM protein, was added to the first well (1), the
dilutions 50/5 ng (2) and 25/2.5 ng (3) are also shown. IL-10 was
measured after 24 hrs of incubation.
doi:10.1371/journal.pone.0070399.g007
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immunosuppressive [51]. Elevated plasma levels of IL-10 were
also reported for patients with melanomas [43–48]. However it is
not quite clear, whether IL-10 is produced by the tumour cells, by
the immune cells or both. When we studied the expression of IL-
10 in melanoma cell lines with measured expression of the TM
protein of HERV-K [11], no IL-10 release was detected in the
supernatant (unpublished).
The fact that HERV-K particles, its TM protein and a synthetic
peptide corresponding to the isu domain induce the same changes
in cytokine expression indicates that the isu domain is the
biologically active domain in the virus. Although the isu domain is
conserved among retroviruses, there are differences in the
sequence of the domain of the gammaretroviruses, of the
corresponding sequence of the lentiviruses and that of HERV-K
(Figure 1). It is of interest that the sequence of the isu domain of
HERV-K is mosaic and contains one amino acids present in all
retroviruses, and in addition: one in the gammaretroviruses, one in
the lentiviruses and three in MMTV (Figure 1b). It is also
important to note that the majority of the HERV-K proviruses,
especially those highly expressed in melanomas, e.g., HERV-K6
[53], contains the sequence present in the TM protein and in the
peptide used in this study. The importance of this domain was
underlined in the case of HIV-1 by mutation in the isu domain.
Six mutations abrogated the influence of the isu domain on
cytokine release totally, while others not [27]. The amino acids
which when mutated abrogated the effect on cytokine release
totally are shown in the sequence of the isu domain of HIV-1 in
Figure 1 in bold. At least three of them are the most conserved
among all retroviruses. The influence of the mutations in the
minor sequences of the isu domain of HIV-1 is difficult to predict,
however analysis of the conformation using the PROTEAN
program showed no significant differences between the variants of
HERV-K.
The mechanism of interaction between the isu domain of the
TM proteins and the immune cells is still unknown.
First, the conformation of the immunosuppressive domain
seems to be important for the immunomodulatory activity.
Whereas conjugates of the isu peptide with a carrier protein or
homopolymers of the isu peptide are active, the monomer did not
show activity [54,55]. When we compared gp41 of HIV-1
produced in human cells with the homopolymers of the isu
peptide of gp41, 700 fold more polymers had to be used to obtain
the same release of IL-10 [27]. The difference is certainly due to
the conformation of the isu domain in the trimeric gp41 compared
with the artificial peptide homopolymer. Differences in the
immunomodulatory activity between retroviruses may explain
the differences in IL-10 induction between PERV and HERV-K
(Figure 7). The slight differences in the expression of cellular genes
induced by the isu peptide polymer of HIV-1 on one site and the
TM protein of HERV-K on the other also argues in favour of that
possibility (Tables S3, S4).
Second, the search for a specific receptor revealed some binding
partners [56–59]. However, their function in the signal transduc-
tion leading to the cytokine modulation is unknown. For
gammaretroviruses and HIV several signal transduction pathways
were described and an inhibition of the protein kinase C by the isu
peptide was shown [60–65]. The donor dependence suggests that
genetic host factors (receptor polymorphism or differences in signal
transduction?) may contribute to the biological activity. It is
important to note, that genes involved in innate immunity such as
SEPP1, FCN1, FCN2 and TREM2 were downregulated. This
allows the virus to manipulate the immune system from the very
first moment of infection.
An interesting example of the complex interaction of the isu
domain with cells of the immune system is given here in detail.
Among the proteins with a higher expression after incubation of
human PBMCs with the TM protein of HERV-K are the
urokinase-type plasminogen activator receptor (uPAR) and the
soluble tumour necrosis factor receptor type II (sTNFRII)
(Figure 4b), similarly as it was observed after incubation with the
isu peptide of HIV-1 and the TM protein of PERV (unpublished).
uPAR is a cell-surface receptor expressed on monocytes and
macrophages, which also exists in soluble and cleaved forms. Its
ligand, the serine-protease uPA, acts proteolytic on the cell
membrane, degrading surrounding extracellular material (ECM).
In addition, uPAR can bind with high affinity a component of the
ECM, vitronectin, and associate to cell surface molecules such as
formyl-peptide receptors (FPR) and integrins to activate signalling
pathways inside the cells. This means that uPAR plays an
important role in cell proliferation/survival and adhesion/
migration, which are crucial events for an efficient immune
response to infectious agent [66]. sTNFRII is a soluble variant of
the extracellular domain of the receptor II of the tumour necrosis
factor (TNF) which is derived from the membrane bound form by
the proteolytic activity of a metalloproteinase. sTNFRII is still able
to bind to TNF and acts as natural inhibitor of TNF by
sequestering soluble TNF and preventing it to bind to its receptor
[67]. Interestingly, expression of the metalloproteinase MMP-1
was also increased by the TM proteins of HERV-K (Figure 5) and
HIV-1 [28].
Taken together, the previously obtained results and the present
study suggest that the immunosuppressive activity may be an
intrinsic property of the TM proteins of retroviruses. Further
studies searching for a putative receptor as well as investigating the
signal transduction pathways leading to the described changes in
the cytokine expression should be carried out.
Materials and Methods
Cells
The human teratocarcinoma cell line GH, kindly provided by
R. Löwer [4], and 293T cells (ATCC CRL11268) were
maintained in DMEM supplemented with 10% heat-inactivated
fetal calf serum, antibiotics and L-glutamine. 293T cells were
infected with stocks of PERV-A/C [68] by spinoculation at 2000 g
for 40 min, splitted and supernatant was collected every second
day.
Cloning, Expression in Yeast Cells and Purification of the
TM Protein of HERV-K
The ectodomain of the transmembrane envelope protein of
HERV-K 108 (which is identical with HML2-HOM, K(C7),
ERVK-6, located on chromosome 7p22.1) [10] was re-cloned into
the expression vector pFPMT121-MFa-His6-TCS [69] with the
signal peptide of the mating factor a (MFa), an inducible promotor
element of the methanol oxidase (MOX) gene and a 6 His. Re-
cloning was achieved using Not I and Bgl II. The expression vector
was transformed into competent yeast cells (H. polymorpha) by
electroporation. Although the MFa signal peptide was present, the
protein was not released into the supernatant. Therefore cells were
disrupted by 8 M urea and 0.3% SDS and the protein was purified
using His tag affinity chromatography.
Preparation of Isu Peptide Conjugates
The HERV-K derived isu peptide was produced and conju-
gated to bovine serum albumin (BSA) as previously described
using EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hy-
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drochloride) [54]. In addition, the isu peptide (KLAN-
QINDLRQTVIWMGDR) (Figure 1) and a randomised peptide
(DILDMRVWKQANGRTLIQN), produced by JPT Berlin, were
used for the preparation of homopolymers by cross-linking using
EDC and NHS (N-hydroxysuccinimid) (Pierce) as recommended
by the supplier.
Isolation of HERV-K and PERV Particles
Supernatants from GH cells producing HERV-K and 293T
cells producing PERV were centrifuged at 1200 g for 10 min and
at 4000 g for 15 min. Then the supernatants were filtered through
0.45 mm filters (Millipore), and centrifuged at 28000 rpm (rotor
SW32Ti, Beckman, Ireland) for 3 hrs. The pellet was resuspended
in PBS and centrifuged through a 20% sucrose cushion at
36000 rpm (rotor SW 50.1Ti, Beckman) for 3 hrs. Virus pellets
from initial 100 ml supernatant were resuspended in 50 ml PBS
and used immediately or stored at 280uC until use. The amount
of TM protein in the preparation was calculated based on the
amount of the Gag (capsid, CA) protein using serial dilutions of
BSA as standard and the assumption that particles contain
approximately 10 times more Gag (CA) than TM protein. Virus
preparations and control supernatants from uninfected cells were
added to PBMCs after six cycles of freeze-thawing procedure.
SDS-PAGE, Native PAGE and Western Blot Analysis
Electrophoresis was performed in Tris-Glycine 4%–20%
gradient gels using SDS Tris-Glycine sample buffer (Novex, Life
technologies Carlsbad, CA, USA). Proteins were transferred onto
Protran BA83 0.2 mm membrane (Whatman GmbH, Dassel,
Germany) at 45 V for 2 hrs. Membranes were blocked with 6%
skimmed milk in PBS with 0.1% Tween 20 (blocking buffer) for
3 hrs at room temperature or overnight at 4uC, incubated for
2 hrs at room temperature with a goat serum against the TM
protein of HERV-K [10,11] (1:300). After five times (5 min each)
washing in PBS with 0.1% Tween 20 (PBS-Tween) the
membranes were incubated for 1 h with anti-goat IgG-HRP
conjugate (Dako Laboratories, Glostrup, Denmark) diluted
1:10000 in blocking buffer. The membranes were washed five
times (5 min each) in PBS-Tween, treated for 1 min with Pierce
ECL Western blotting substrate (Pierce, Rockford, IL, USA) and
exposed to CL-XPosure film (Thermo Scientific, USA). The
molecular mass was determined using a mixture of the following
markers: Page Ruler Plus Prestained Protein Ladder (Fermentas
Life Science) and Magic Mark XP Western Protein Standard
(Invitrogen).
Isolation of Human PBMCs and Murine Spleen Cells
Human PBMCs were isolated from whole blood of healthy
donors by Ficoll-Hypaque (PAA Laboratories, Austria) density
centrifugation using Leucosep tubes (Greiner, Germany). Isolated
PBMCs were cultivated with the HERV-K TM protein or BSA at
37uC in RPMI 1640 with 10% fetal calf serum (FCS, Biochrome
AG, Berlin, Germany) which had been selected for very low
induction of IL-10 in normal PBMCs or medium alone. Spleen
cells were obtained from BALB/c mice by mechanical disruption
and subsequently washed and incubated in RPMI 1640 with 10%
FCS.
Proliferation Assays
Proliferation assays using 3H-thymidine were performed by
stimulating 3.256106 donor PBMCs or murine spleen cells with
10 mg/ml Concanavalin A (ConA, Sigma) in the presence or
absence of the HERV-K TM protein or the isu peptide conjugated
to BSA. After incubation at 37uC and 5% CO2 for 40 hrs
3H-
thymidine (1 mCi/well) was added and the cells were incubated for
additional 24 h at 37uC and then harvested. Counts per minute
(cpm) were determined using a Micro Beta Trilux Scintillation and
Luminescence counter (Perkin Elmer) or by a 96-well plate beta-
counter as described previously [28,54]. In addition, Alamar blue
proliferation assays were performed. 3.256106 donor PBMCs
were incubated with the HERV-K TM protein or with control
BSA, with and without 10 mg/ml Concanavalin A (ConA, Sigma).
After 48 hrs at 37uC and 5% CO2 20 ml of Alamar blue
(Biosource International) were added to each well and after
additional incubation for 8 hrs the plates were measured in an
ELISA reader Spectra Classic (Tecan) at wavelengths 560 nm and
620 nm. The D values of both results were counted as the specific
adsorption.
Enzyme-linked Immunosorbent Assays for IL-10
Supernatants from donor PMBCs either untreated or treated for
24 hrs with the TM protein of HERV-K were collected by
centrifugation at 2000 g for 10 min and tested for IL-10 by
ELISA according to the protocol of the supplier (BD Biosciences,
San Diego, USA).
Cytokine Arrays
Cytokine release in the supernatant of treated or untreated
donor PBMCs were measured by a membrane-based cytokine
array VI (RayBiotech, Inc.) after 24 hrs allowing measurement of
62 different cytokines.
RNA Isolation from PBMCs
Total RNA was isolated from donor PBMCs using the RNeasy
kit (Qiagen, Hilden, Germany). The RNA concentration was
measured using a NanoDrop spectrometer ND-100 (PEQLAB),
and RNA specimens were used immediately or kept at 280uC
before use.
Microarray
Total RNA was prepared as described above. An RNA integrity
numbers (RIN) of 9.1 and 8.8 were determined for the RNA from
PBMCs cultured with medium or the TM protein of HERV-K,
respectively (RIN 10 is the highest). The microarray was
performed by IMGM Laboratories, Munich. 0.5 mg of total
RNA were converted into digoxigenin (DIG)-labeled cRNA in a
reverse transcriptase in vitro transcription (RT-IVT), 10 mg were
fragmented and hybridised using a Human Genome Survey
Microarray V2.0 plate from Applied Biosystems. After washing, an
anti-DIG-AP-conjugate (Roche, Germany) was applied and signals
were detected with an AB1700 Microarray Reader.
Ethical Statement
The use of human blood has been approved by the ethical
commission at the Medical Faculty of the Humboldt University
Berlin. Written informed consent was provided by study partic-
ipants. This study was carried out in strict accordance with the
German Animal Protection Act and was approved by the
Landesamt für Gesundheit und Soziales (LAGeSo) Berlin. All
efforts were made to minimize suffering.
Supporting Information
Figure S1 Characterisation of the TM protein of HERV-
K produced in yeast cells. a, SDS-PAGE of the purified
protein stained by Coomassie blue. Arrows indicate the 20, 30 and
32 kDa proteins. b, Western blot analysis using an antibody
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specific for the His-tag. c,Western blot analysis using a goat serum
specific for the TM protein produced in E. coli. M -– marker
proteins, 1– TM protein produced in yeast cells and purified by
His-tag affinity chromatography. 2– bovine serum albumin, 3 -
TM protein produced as calmodulin binding fusion protein in E.
coli. d, Amino acid sequence of the entire TM protein of HERV-K
and the epitopes recognised by the goat serum after immunisation
with the TM protein produced in E. coli. Blue – sequence of the
ectodomain of the TM protein used for immunisation, red – Asn-
Xaa-Ser/Thr sequences, green – immunosuppressive domain,
underlined – potential glycosylation site according the NetNGlyc
1.0 program, brown – Cys – Cys loop.
(TIF)
Table S1 Examples of the sequences of the isu domain
of different HERV-K proviruses. Mutations are marked in
red.
(DOCX)
Table S2 Abbreviations and full names of the cytokines
tested for (see Fig. 4). Cytokines with increased expression are
shown in red.
(DOCX)
Table S3 Results of the microarray analysis: Up-
regulated genes.
(DOCX)
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